Today |
On The Fly
| ShowHide Related Items >><< - 11:43 Today
- User reports indicate Verizon experiencing issues, says DownDetector
- 09:00 Today
- Verizon sees FY21 adjusted effective tax rate 23%-25%
- 07:08 Today
- Verizon reports Business retail postpaid net additions 346K
- 07:06 Today
- Verizon reports Q4 Consumer retail postpaid net additions of 357K
- 08:50 Today
- Vaxart announces additional preclinical COVID-19 oral vaccine data
- 11/16/20
- Vaxart hosting KOL panel call for investors
- 11/12/20
- Vaxart announces additional data from Hamster Challenge study
- 10/14/20
- Vaxart discloses receipt of grand jury subpoena, SEC document request
- $57.67 /
+13.33 (+30.06%) - 08:11 Today
- Vir Biotechnology announces data from ongoing Phase 1 trial of VIR-3434
- 01/12/21
- Gilead, Vir Biotechnology establish collaboration for chronic HBV
- 01/12/21
- Gilead, Vir collaborate to explore combination strategies for HBV cure
- 01/12/21
- Vir Biotechnology, GlaxoSmithKline to evaluate VIR-7832 in COVID-19 patients
- 07:03 Today
- Regeneron reports 'positive' results from Phase 3 trial evaluating REGEN-COV
- 01/13/21
- Regeneron awarded $2.625B government contract
- 01/12/21
- Roche confirms U.S to buy additional doses of Regeneron's Cov-19 cocktail
- 01/12/21
- Regeneron says HHS, DOD to purchase more COVID-19 antibody cocktail doses
- 12/01/20
- PepsiCo, UEFA Champions League continue global partnership
- 11/24/20
- Dick's Sporting names Lauren Hobart as CEO, succeeding Edward Stack
- 01/25/21
- Longview Acquisition Corp., Butterfly Network: Todd Fruchterman to become CEO
- 01/17/21
- Fly Intel: Top five weekend stock stories
- 12/21/20
- Apogee Enterprises names Ty Silberhorn as CEO
- 12/03/20
- 3M to take $250M-$300M in restructuring actions, 2,900 positions to be impacted
- $335.39 /
-8.495 (-2.47%) - 11:51 Today
- Lockheed Martin sees reducing office space by 2M square feet
- 11:33 Today
- Lockheed Martin sees ending 2021 with over $5B in cash
- 11:30 Today
- Lockheed Martin sees Biden administration bringing continuity to U.S. defense
- 11:21 Today
- Lockheed Martin sees companywide sales up 4% this year
- 09:30 Today
- Johnson & Johnson says 'comfortable' meeting COVID-19 vaccine demand
- 09:21 Today
- Johnson & Johnson sees no biosimilar entrants in Pharmaceutical segment in FY21
- 09:16 Today
- Johnson & Johnson sees FY21 adjusted pre-tax operating margin up ~200 bps
- 09:06 Today
- Johnson & Johnson says Phase 3 COVID-19 vaccine study results due next week
- $186.56 /
+27.85 (+17.55%) - 09:02 Today
- Beyond Meat jumps 35% to $215.42 after forming JV with PepsiCo
- 08:32 Today
- PepsiCo, Beyond Meat establish The PLANeT Partnership
- 01/15/21
- Beyond Meat announces plans for new global headquarters
- 01/14/21
- Taco Bell exploring new plant-based protein with Beyond Meat
- 07:11 Today
- American Express reports Q4 Global Merchant, Network Services net income $208M
- 07:10 Today
- American Express reports Q4 Global Commercial Services net income $538M
- 07:09 Today
- American Express reports Q4 Global Consumer Services Group net income $1.1B
- 01/15/21
- American Express reports December write-off rate 1.6% vs. 1.9% month prior
- 01/15/21 B. Riley Securities
- Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
- 01/14/21 Morgan Stanley
- 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
- 01/14/21 Oppenheimer
- Essa Pharma price target raised to $20 from $9 at Oppenheimer
- 12/29/20 Piper Sandler
- Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
- 01/19/21
- Fly Intel: Top five analyst upgrades
- 01/19/21 JPMorgan
- American Express upgraded to Overweight from Underweight at JPMorgan
- 01/12/21 Susquehanna
- American Express price target raised to $124 from $110 at Susquehanna
- 01/07/21 Wells Fargo
- American Express selloff on WSJ story overdone, says Wells Fargo
- 11:24 Today MoffettNathanson
- Verizon path to outperformance 'narrower' due to auction, says MoffettNathanson
- 06:35 Today JMP Securities
- Synchrony price target raised to $43 from $36 at JMP Securities
- 12/02/20
- Fly Intel: Top five analyst upgrades
- 12/02/20 MoffettNathanson
- Verizon upgraded to Buy from Neutral at MoffettNathanson
- 01/13/21 Deutsche Bank
- 3M named 'Catalyst Call: Buy Idea' at Deutsche Bank
- 01/07/21 BofA
- 3M downgraded to Underperform from Neutral at BofA
- 10/07/20
- Fly Intel: Top five analyst upgrades
- 10/07/20 JPMorgan
- 3M price target raised to $170 from $159 at JPMorgan
- 09:55 Today Piper Sandler
- Regeneron passive vaccine data 'compelling,' says Piper Sandler
- 01/25/21
- Fly Intel: Top five analyst upgrades
- 01/25/21 BMO Capital
- Regeneron upgraded to Outperform from Market Perform at BMO Capital
- 01/25/21 BMO Capital
- Regeneron upgraded to Outperform from Market Perform at BMO Capital
- $57.67 /
+13.33 (+30.06%) - 01/20/21 H.C. Wainwright
- Vir Biotechnology price target raised to $125 from $100 at H.C. Wainwright
- 12/24/20 Baird
- Baird maintains 'profound skepticism' of Vir's COVID antibody after Lilly data
- 10/07/20 Goldman Sachs
- Goldman says Lilly comments support need for multiple COVID-19 antibody makers
- 10/07/20 H.C. Wainwright
- Vir Biotechnology price target raised to $100 from $80 at H.C. Wainwright
- $186.56 /
+27.85 (+17.55%) - 11:09 Today William Blair
- Beyond Meat will access Pepsi's systems for new products, says William Blair
- 10:33 Today Wells Fargo
- JV doesn't change near-term trajectory for Beyond Meat, says Wells Fargo
- 10:05 Today JPMorgan
- Beyond Meat move higher should be 'faded,' but maybe not yet, says JPMorgan
- 09:46 Today Oppenheimer
- Beyond Meat JV with Pepsi an 'attractive longer-term driver,' says Oppenheimer
- 01/19/21 Bernstein
- PepsiCo initiated with an Underperform at Bernstein
- 11/18/20 B. Riley Securities
- Vaxart price target lowered to $16 from $22 at B. Riley Securities
- 10/13/20 B. Riley Securities
- B. Riley views Vaxart as key player in 'second wave' of Covid vaccines
- 09/09/20 B. Riley Securities
- Astra trial hold opens window for other vaccine candidates, says B. Riley FBR
- 08/12/20 H.C. Wainwright
- Vaxart price target raised to $17 from $7 at H.C. Wainwright
- $335.39 /
-8.495 (-2.47%) - 01/07/21 Baird
- Lockheed Martin downgraded to Neutral from Outperform at Baird
- 01/07/21 Jefferies
- Jefferies downgrades Aerojet Rocketdyne to Hold, sees higher bid as unlikely
- 12/22/20 Credit Suisse
- Lockheed Martin price target raised to $409 from $400 at Credit Suisse
- 12/22/20 Truist
- Aerojet Rocketdyne downgraded to Hold from Buy at Truist
- 07:04 Today
- Verizon sees FY21 EPS $5.00-$5.15, consensus $4.98
- 07:03 Today
- Verizon reports Q4 adjusted EPS $1.21, consensus $1.17
- 11/12/20
- Vaxart reports Q3 EPS (8c), consensus (9c)
- $57.67 /
+13.33 (+30.06%) - 11/10/20
- Vir Biotechnology reports Q3 EPS (67c), consensus (60c)
- 08/11/20
- Vir Biotechnology reports Q2 EPS (27c), consensus (62c)
- 11/05/20
- Regeneron reports Q3 EPS $8.36, consensus $7.13
- 11/04/20
- Notable companies reporting before tomorrow's open
- 08/05/20
- Regeneron reports Q2 EPS $7.16, consensus $5.98
- 10/01/20
- PepsiCo sees FY core EPS about $5.50, consensus $5.36
- 10/01/20
- PepsiCo reports Q3 adjusted EPS $1.66, consensus $1.49
- 09/30/20
- Notable companies reporting before tomorrow's open
- 06:36 Today
- 3M sees FY21 EPS $9.20-$9.70, consensus $9.52
- 06:34 Today
- 3M reports Q4 adjusted EPS $2.38, consensus $2.15
- $335.39 /
-8.495 (-2.47%) - 07:32 Today
- Lockheed Martin sees FY21 EPS $26.00-$26.30, consensus $26.11
- 07:30 Today
- Lockheed Martin reports Q4 EPS $6.38, consensus $6.41
- 06:50 Today
- Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45
- 06:46 Today
- Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82
- 01/25/21
- Notable companies reporting before tomorrow's open
- $186.56 /
+27.85 (+17.55%) - 11/09/20
- Beyond Meat reports Q3 adj. EPS (28c), consensus 5c
- 11/09/20
- Notable companies reporting after market close
- 08/04/20
- Beyond Meat 2020 outlook remains suspended
- 08/04/20
- Beyond Meat reports Q2 EPS (2c), consensus (4c)
- 07:04 Today
- American Express reports Q4 EPS $1.76, consensus $1.31
- 01/25/21
- Fly Intel: What to watch in credit card space earnings reports
|
Options
| ShowHide Related Items >><< - $21.18 /
+1.2801 (+6.43%) - 01/04/21
- XL Fleet falls -14.5%
- 12/31/20
- Exelon reports 5.3% passive stake in XL Fleet
- 12/23/20
- XL Fleet trading resumes after volatility halt, shares up 62% to $28.34
- 12/23/20
- XL Fleet rises 44.2%
- 10/05/20
- Macerich announces all 47 retail properties to be fully open for business
- 09/10/20
- Macerich announces 44 of 47 retail properties reopened
- 08/12/20
- Macerich holder Passive Investment reports 6.8% stake, saw shares 'undervalued'
- 09:30 Today
- Johnson & Johnson says 'comfortable' meeting COVID-19 vaccine demand
- 09:21 Today
- Johnson & Johnson sees no biosimilar entrants in Pharmaceutical segment in FY21
- 09:16 Today
- Johnson & Johnson sees FY21 adjusted pre-tax operating margin up ~200 bps
- 09:06 Today
- Johnson & Johnson says Phase 3 COVID-19 vaccine study results due next week
- 08:38 Today
- General Electric: Aviation to see continued challenges in 2021
- 08:18 Today
- GE: 2020 orders down 17%, with 95% of the pressure aviation-related
- 08:07 Today
- General Electric CEO sees 'considerable improvement' from mid-2020
- 08:03 Today
- General Electric CEO: 'It's hard to think of a tougher year' than 2020
- 01/12/21
- Jason Klarman named president of FOX Nation
- 12/16/20
- Fox News Media signs Laura Ingraham to new multiyear deal
- 12/09/20
- Fox News Media to launch streaming weather service FOX Weather in 2021
- 12/03/20
- Flutter agrees to acquire 37.2% interest in FanDuel from Fastball for $4.175B
- 01/07/21 JPMorgan
- GE shares 'de-coupled from long term fundamentals,' says JPMorgan
- 12/16/20 DZ Bank
- General Electric upgraded to Hold from Sell at DZ Bank
- 12/10/20 Gordon Haskett
- SEC settlement clears path for GE to issue shares, says Gordon Haskett
- 12/10/20 Argus
- General Electric price target raised to $14 from $10 at Argus
- 12/21/20 JPMorgan
- JPMorgan changes ratings in REIT, Real Estate Services sectors into 2021
- 12/21/20 JPMorgan
- Macerich downgraded to Underweight from Neutral at JPMorgan
- 12/15/20 Citi
- Macerich downgraded to Sell from Neutral at Citi
- 12/14/20 KeyBanc
- Macerich upgraded to Sector Weight from Underweight at KeyBanc
- $21.18 /
+1.2801 (+6.43%) - 01/22/21
- Fly Intel: Top five analyst initiations
- 01/22/21 BTIG
- XL Fleet initiated with a Buy at BTIG
- 01/15/21 B. Riley Securities
- Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
- 01/14/21 Morgan Stanley
- 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
- 01/14/21 Oppenheimer
- Essa Pharma price target raised to $20 from $9 at Oppenheimer
- 12/29/20 Piper Sandler
- Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
- 10/30/20 Morgan Stanley
- Morgan Stanley says ad recovery lifts outlook for Fox Corp.
- 07/15/20 Guggenheim
- Fox Corp. price target lowered to $29 from $32 at Guggenheim
- 05/28/20 Jefferies
- Flutter Entertainment share sale a 'confident, proactive step,' says Jefferies
- 04/13/20 Citi
- Fox Corp. resumed with a Neutral at Citi
- 11/05/20
- Macerich reports Q3 FFO 52c, consensus 54c
- 08/11/20
- Macerich not providing guidance at this time
- 08/11/20
- Macerich reports Q2 EPS (18c), consensus (30c)
- 06:50 Today
- Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45
- 06:46 Today
- Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82
- 06:24 Today
- General Electric sees FY21 adjusted EPS 15c-25c, consensus 38c
- 06:21 Today
- General Electric reports Q4 adjusted EPS 8c, consensus 9c
- 01/25/21
- Notable companies reporting before tomorrow's open
- 11/03/20
- Fox Corp. reports Q1 adjusted EPS $1.18, consensus 74c
- 08/04/20
- Fox Corp. reports Q4 adj. EPS 62c, consensus 57c
- 08/04/20
- Notable companies reporting after market close
- $21.18 /
+1.2801 (+6.43%) - 12/23/20
- XL Fleet jumps after Citron puts $60 price target on shares
- 12/23/20
- Citron announces long position in XL Fleet with $60 price target
- 01/22/21
- J&J director says company could boost vaccine availability by spring, CNBC says
- 01/13/21
- Johnson & Johnson's one-dose COVID-19 vaccine appears 'promising,' CNBC says
- 01/13/21
- J&J chief science officer sees possible vaccine approval by March, Reuters says
- 01/13/21
- J&J sees U.S. decision on COVID-19 vaccine candidate by March, Bloomberg says
- 01/14/21
- GE says Siemens stole trade secrets in bid to rig contracts , Reuters reports
- 01/11/21
- GE to pause donations to lawmakers who voted against Biden win, Bloomberg says
- 01/09/21
- Some century-old stocks still deliver, Barron's says
- 01/05/21
- GE board won't attempt to claw back former CEO's pay, WSJ reports
- 11/12/20
- Trump aiming to challenge Fox News with own digital media company, Axios says
- 10/14/20
- Amazon reaches deal to stream NFL playoff game, MarketWatch reports
- 07/30/20
- Blue Jays-Phillies series postponed after positive virus tests, Sportsnet says
- 07/28/20
- Marlins season on pause due to COVID-19 outbreak, Miami Herald reports
- 01/14/21
- Fly Intel: Wall Street's top stories for Thursday
- 01/14/21
- Fly Intel: Wall Street's top stories at midday
- 01/13/21
- Fly Intel: Wall Street's top stories for Wednesday
- 09:03 Today
- Fly Intel: Pre-market Movers
- 11/24/20
- Target upgrade, Microsoft initiation among today's top calls on Wall Street
- 10/28/20
- Fly Intel: Wall Street's top stories for Wednesday
- 10/28/20
- Fly Intel: Wall Street's top stories at midday
- 12/04/20
- Bet On It: Michigan clears path for online gambling
- 11/14/20
- Week in review: How Trump's policies moved stocks
- 11/12/20
- Fly Intel: Wall Street's top stories for Thursday
- 08/04/20
- Fly Intel: Wall Street's top stories for Tuesday
- $21.18 /
+1.2801 (+6.43%) - 01/22/21
- Early notable gainers among liquid option names on January 22nd
- 01/07/21
- Early notable gainers among liquid option names on January 7th
- 12/30/20
- Largest borrow rate increases among liquid names
- 12/23/20
- XL Fleet Corp (Class A Stock) call volume above normal and directionally bullish
- 01/25/21
- Early notable gainers among liquid option names on January 25th
- 01/19/21
- Early notable gainers among liquid option names on January 19th
- 01/14/21
- Early notable gainers among liquid option names on January 14th
- 01/12/21
- Largest borrow rate increases among liquid names
- 12/01/20
- Johnson & Johnson call volume above normal and directionally bullish
- 10/13/20
- Unusually active option classes on open October 13th
- 09/23/20
- Unusually active option classes on open September 23rd
- 08/24/20
- Unusually active option classes on open August 24th
- 01/06/21
- General Electric call volume above normal and directionally bullish
- 12/23/20
- Notable open interest changes for December 23rd
- 12/22/20
- General Electric call volume above normal and directionally bullish
- 10/28/20
- Early notable gainers among liquid option names on October 28th
- 12/24/20
- Early notable gainers among liquid option names on December 24th
- 09/08/20
- Early notable gainers among liquid option names on September 8th
|
Hot Stocks
| ShowHide Related Items >><< - 09:21 Today
- Johnson & Johnson sees no biosimilar entrants in Pharmaceutical segment in FY21
- 09:16 Today
- Johnson & Johnson sees FY21 adjusted pre-tax operating margin up ~200 bps
- 09:06 Today
- Johnson & Johnson says Phase 3 COVID-19 vaccine study results due next week
- 06:49 Today
- Genmab reports $4.109B in worldwide net trade sales of Darzalex in 2020
- 01/15/21 B. Riley Securities
- Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
- 01/14/21 Morgan Stanley
- 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
- 01/14/21 Oppenheimer
- Essa Pharma price target raised to $20 from $9 at Oppenheimer
- 12/29/20 Piper Sandler
- Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
- 06:50 Today
- Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45
- 06:46 Today
- Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82
- 01/25/21
- Notable companies reporting before tomorrow's open
- 01/22/21
- J&J director says company could boost vaccine availability by spring, CNBC says
- 01/13/21
- Johnson & Johnson's one-dose COVID-19 vaccine appears 'promising,' CNBC says
- 01/13/21
- J&J chief science officer sees possible vaccine approval by March, Reuters says
- 01/13/21
- J&J sees U.S. decision on COVID-19 vaccine candidate by March, Bloomberg says
- 09:03 Today
- Fly Intel: Pre-market Movers
- 01/14/21
- Fly Intel: Wall Street's top stories for Thursday
- 01/14/21
- Fly Intel: Wall Street's top stories at midday
- 01/13/21
- Fly Intel: Wall Street's top stories for Wednesday
- 12/01/20
- Johnson & Johnson call volume above normal and directionally bullish
- 10/13/20
- Unusually active option classes on open October 13th
- 09/23/20
- Unusually active option classes on open September 23rd
- 08/24/20
- Unusually active option classes on open August 24th
|
Hot Stocks
| ShowHide Related Items >><< - 09:16 Today
- Johnson & Johnson sees FY21 adjusted pre-tax operating margin up ~200 bps
- 09:06 Today
- Johnson & Johnson says Phase 3 COVID-19 vaccine study results due next week
- 06:49 Today
- Genmab reports $4.109B in worldwide net trade sales of Darzalex in 2020
- 01/25/21
- Minnesota DOH reports first U.S. case of COVID-19 variant first found in Brazil
- 01/15/21 B. Riley Securities
- Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
- 01/14/21 Morgan Stanley
- 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
- 01/14/21 Oppenheimer
- Essa Pharma price target raised to $20 from $9 at Oppenheimer
- 12/29/20 Piper Sandler
- Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
- 06:50 Today
- Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45
- 06:46 Today
- Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82
- 01/25/21
- Notable companies reporting before tomorrow's open
- 01/22/21
- J&J director says company could boost vaccine availability by spring, CNBC says
- 01/13/21
- Johnson & Johnson's one-dose COVID-19 vaccine appears 'promising,' CNBC says
- 01/13/21
- J&J chief science officer sees possible vaccine approval by March, Reuters says
- 01/13/21
- J&J sees U.S. decision on COVID-19 vaccine candidate by March, Bloomberg says
- 09:03 Today
- Fly Intel: Pre-market Movers
- 01/14/21
- Fly Intel: Wall Street's top stories for Thursday
- 01/14/21
- Fly Intel: Wall Street's top stories at midday
- 01/13/21
- Fly Intel: Wall Street's top stories for Wednesday
- 12/01/20
- Johnson & Johnson call volume above normal and directionally bullish
- 10/13/20
- Unusually active option classes on open October 13th
- 09/23/20
- Unusually active option classes on open September 23rd
- 08/24/20
- Unusually active option classes on open August 24th
|
Conference/Events
| ShowHide Related Items >><< - 01/25/21
- LinkedIn names Dan Shapero as first ever COO
- 01/22/21
- Microsoft increases pricing for Xbox Live Gold
- 01/22/21
- SAP, Microsoft expand partnership
- 01/20/21
- EU fines Valve, Capcom, ZeniMax, others EUR7.8M for 'geo-blocking' practices
- 07:24 Today
- AbCellera announces results from BLAZE-1 trial with Eli Lilly
- 06:54 Today
- Eli Lilly announces BLAZE-1 trial meets primary endpoint
- 01/22/21
- Eli Lilly completes acquisition of Prevail Therapeutics
- 01/21/21
- AbCellera-discovered antibody prevented COVID-19 in nursing homes, reduced risks
- 12/21/20
- Q2 Solutions teams with Adaptive Biotechnologies to market immunoSEQ Assay
- 12/16/20
- Iqvia in pact with Servier to 'reinvent' its R&D clinical development processes
- 11/18/20
- Iqvia's Rittenmeyer sells over 40,000 common shares
- 11/13/20
- Third Point takes stake in PG&E, boosts Alibaba stake, exits Baxter
- 01/15/21
- Halozyme says Janssen receives FDA approval of Darzalex Faspro
- 12/23/20
- Halozyme announces EC approval of Roche fixed-dose combination with Enhanze
- 12/07/20
- Halozyme's Kelly sells 35,086 common shares
- 12/02/20
- Halozyme's Kelley sells 31,792 common shares
- 12/16/20
- Merck, Eisai: KEYTRUDA plus LENVIMA showed significant improvement in OS
- 12/10/20
- Biogen submits aducanumab J-NDA to Ministry of Health, Labor and Welfare
- 11/10/20
- Merck reports KEYTRUDA plus LENVIMA trial met primary endpoint
- 11/09/20
- Eisai presents latest BAN2401 data at CTAD
- 01/22/21
- Bristol-Myers announces approval of Opdivo plus Cabometyx for carcinoma
- 01/20/21
- Bristol-Myers: FDA accepts for Priority Review sBLA for Opdivo combination
- 01/11/21
- Bristol-Myers CEO: Our strategy for growth is based on innovation
- 01/11/21
- Illumina announces new and expanded oncology partnerships
- 01/11/21
- AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint
- 01/11/21
- Biogen study to develop biomarkers of cognitive health using Apple devices
- 01/08/21
- Biogen treats first patient in RESPOND study of SPINRAZA
- 01/05/21
- Biogen, ViGeneron enter collaboration agreement to develop gene therapy products
- 06:07 Today
- AstraZeneca's Symbicort Turbuhaler approved in China for mild asthma
- 01/25/21
- Minnesota DOH reports first U.S. case of COVID-19 variant first found in Brazil
- 01/25/21
- AstraZeneca's Calquence approved in Japan for CLL treatment
- 01/25/21
- AstraZeneca's Calquence met primary endpoint in head-to-head trial vs. ibrutinib
- 01/13/21
- Alexion further pauses global Phase 3 study of Ultomiris
- 01/13/21
- Alexion to pause further enrollment in Phase 3 study of ULTOMIRIS
- 12/13/20
- Fly Intel: Top five weekend stock stories
- 12/12/20
- AstraZeneca sees 'robust and sustainable' core EPS accretion from Alexion deal
- 01/25/21
- AbbVie announces EC approval of Rinvoq for PsA and ankylosing spondylitis
- 01/25/21
- Alector doses first patient in Phase 2 study of AL002 in Alzheimer's
- 01/13/21
- Genmab achieves $40M milestone in AbbVie collaboration
- 01/12/21
- Immunovant appoints Rita Jain as Chief medical Officer
- 01/06/21 RBC Capital
- AbbVie named one of top stocks to own in 2021 by RBC Capital
- 12/17/20 Stifel
- Outcome in Evolus IP case 'better than most investors expected,' says Stifel
- 12/16/20 SVB Leerink
- AbbVie price target raised to $128 from $119 at SVB Leerink
- 12/15/20 Mizuho
- AbbVie price target raised to $117 from $111 at Mizuho
- 01/08/21 Raymond James
- Alexion downgraded to Market Perform from Outperform at Raymond James
- 12/16/20 Truist
- Alexion downgraded to Hold from Buy at Truist
- 12/15/20 Truist
- Argenx price target raised to $350 from $275 at Truist
- 12/14/20 Citi
- Alexion downgraded to Neutral from Buy at Citi
- 01/22/21 Barclays
- AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays
- 01/19/21 BTIG
- Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
- 01/15/21 Berenberg
- AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
- 01/15/21
- Fly Intel: Top five analyst initiations
- 01/14/21 Truist
- Truist says FDA wouldn't be discussing label if not going to approve aducanumab
- 01/11/21 Goldman Sachs
- Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
- 12/04/20 Mizuho
- Sage Therapeutics upgraded to Buy from Neutral at Mizuho
- 12/01/20 Truist
- Sage Therapeutics price target raised to $70 from $60 at Truist
- 01/20/21 William Blair
- Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
- 01/20/21 Citi
- Citi opens 'negative Catalyst Watch' on Bristol-Myers
- 12/15/20 Goldman Sachs
- Bristol-Myers upgraded to Conviction Buy from Buy at Goldman Sachs
- 12/09/20 Mizuho
- Pentwater seeks to replace Bristol-Myers Squibb CVR trustee, says Mizuho
- 11/05/20 Jefferies
- Eisai upgraded to Buy from Hold at Jefferies
- 09/08/20 Jefferies
- Eisai downgraded to Hold from Buy at Jefferies
- 01/25/21 BMO Capital
- Halozyme price target raised to $65 from $56 at BMO Capital
- 01/21/21 Benchmark
- Halozyme price target raised to $59 from $46 at Benchmark
- 01/14/21 Piper Sandler
- Halozyme price target raised to $50 from $42 at Piper Sandler
- 01/11/21 Benchmark
- Phesgo EU approval/Horizon deal fuel Halozyme increased guidance, says Benchmark
- 12/18/20 Mizuho
- Iqvia price target raised to $200 from $190 at Mizuho
- 10/22/20 Deutsche Bank
- Iqvia price target raised to $196 from $180 at Deutsche Bank
- 10/21/20 UBS
- Iqvia price target raised to $224 from $204 at UBS
- 10/21/20 Morgan Stanley
- Iqvia price target raised to $195 from $182 at Morgan Stanley
- 01/20/21 Citi
- Citi opens 'positive Catalyst Watch' on Eli Lilly into Alzheimer's data
- 01/19/21 Roth Capital
- Merus price target raised to $32 from $19 at Roth Capital
- 01/19/21
- Fly Intel: Top five analyst upgrades
- 01/19/21 Mizuho
- Eli Lilly upgraded to Buy from Neutral at Mizuho
- 01/25/21 Morgan Stanley
- Morgan Stanley says market closer to recognizing Alphabet sum-of-the-parts value
- 01/25/21 DA Davidson
- Box downgraded to Neutral from Buy at DA Davidson
- 01/22/21 RBC Capital
- Varonis price target raised to $200 from $165 at RBC Capital
- 10/27/20
- Microsoft sees Q2 Productivity and Business Processes revenue $12.75B-$13B
- 10/27/20
- Microsoft reports Q1 EPS $1.82, consensus $1.54
- 10/27/20
- Notable companies reporting after market close
- 12/15/20
- Eli Lilly sees FY21 EPS $7.75-$8.40, consensus $8.07
- 12/15/20
- Eli Lilly raises FY20 EPS view to $7.45-$7.65 from $7.20-$7.40, consensus $7.32
- 12/02/20
- Eli Lilly says updated purchase of LY-CoV555 to boost FY20 EPS view by 25c
- 10/27/20
- Eli Lilly backs FY20 adj. EPS view $7.20-$7.40, consensus $7.28
- 10/20/20
- Iqvia sees FY21 EPS $7.65-$7.95, consensus $7.57
- 10/20/20
- Iqvia sees Q4 EPS $1.93 - $2.03, consensus $1.97
- 10/20/20
- Iqvia raises FY20 EPS view to $6.25 - $6.35 from $6.10 - $6.30, consensus $6.18
- 10/20/20
- Iqvia reports Q3 EPS $1.63, consensus $1.52
- 01/11/21
- Halozyme sees FY21 GAAP EPS $1.40-$1.55, consensus $1.79
- 11/23/20
- Halozyme raises FY20 EPS view to 90c-95c from 80c-85c, consensus 86c
- 11/02/20
- Halozyme raises FY20 GAAP EPS view to 80c-85c from 60c-75
- 11/02/20
- Halozyme reports Q1 EPS 25c, consensus 19c
- 11/05/20
- Bristol-Myers backs FY21 EPS view $7.15-$7.45, consensus $7.39
- 11/05/20
- Bristol-Myers raises FY20 EPS view to $6.25-$6.35 from $6.10-$6.25
- 11/05/20
- Bristol-Myers reports Q3 EPS $1.63, consensus $1.49
- 11/04/20
- Notable companies reporting before tomorrow's open
- 10/21/20
- Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00
- 10/21/20
- Biogen reports Q3 adjusted EPS $8.84, consensus $8.13
- 10/20/20
- Notable companies reporting before tomorrow's open
- 11/05/20
- AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage
- 11/05/20
- AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year
- 07/30/20
- AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS
- 07/30/20
- AstraZeneca reports Q2 core EPS 96c, up 31% at CER
- 10/29/20
- Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95
- 10/29/20
- Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60
- 10/28/20
- Notable companies reporting before tomorrow's open
- 10/30/20
- AbbVie sees Q4 adjusted EPS $2.83-$2.85, consensus $2.90
- 10/30/20
- AbbVie raises FY20 revenue view to ~$45.7B from ~$45.5B, consensus $45.48B
- 10/30/20
- AbbVie raises FY20 adj. EPS view to $10.47-$10.49 from $10.35-$10.45
- 10/30/20
- AbbVie reports Q3 adjusted EPS $2.83, consensus $2.76
- 01/22/21
- YouTube enables HDR support on Xbox gaming systems, Verge reports
- 01/19/21
- FireEye releases tool for auditing networks after SolarWinds hack, ZDNet says
- 01/14/21
- IBM buying cloud computing consultant Taos Mountain, WSJ reports
- 01/13/21
- Lucasfilm partners with Ubisoft to make open-world 'Star Wars' game, Wired says
- 12/30/20
- Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says
- 12/23/20
- Judge rules against White House drug pricing rule, Reuters says
- 11/23/20
- EU seeks easier access to generic medicines, Reuters says
- 11/20/20
- Trump to release new rules aimed at lowering drug prices, WSJ reports
- 10/05/20
- Bristol-Myers to buy MyoKardia for $13.1B, or $225/share in cash, WSJ reports
- 11/07/20
- Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says
- 11/07/20
- FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says
- 09/28/20
- Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says
- 09/28/20
- Biogen loses appeal ruling on MS drug Rebif, Bloomberg says
- 01/25/21
- EU urges AstraZeneca to accelerate COVID vaccine deliveries, Reuters reports
- 01/24/21
- Germany expects AstraZeneca to deliver 3M vaccine doses in February,Reuters says
- 01/22/21
- AstraZeneca to slash EU COVID-19 vaccine deliveries by 60% in Q1, Reuters says
- 01/22/21
- EU to see delay of AstraZeneca COVID vaccine delivery, FT reports
- 10/09/20
- Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports
- 12/16/20
- AbbVie unit wins ITC trade secret case against Evolus, Bloomberg says
- 12/16/20
- AbbVie unit wins ITC trade secret case against Evolus, Bloomberg says
- 12/09/20
- Former Allergan CEO's SPAC to merge with HydraFacial Co, WSJ reports
- 12/04/20
- Ironwood adds 'serial seller' to board, Dealreporter says
- 01/25/21
- GameStop jumps above $100 in volatile trading despite double downgrade to sell
- 01/22/21
- Disney, Ford upgrades among today's top calls on Wall Street
- 01/19/21
- Fly Intel: Wall Street's top stories for Tuesday
- 01/19/21
- Fly Intel: Wall Street's top stories at midday
- 01/21/21
- Fly Intel: Wall Street's top stories for Thursday
- 01/21/21
- Fly Intel: Wall Street's top stories at midday
- 10/20/20
- Fly Intel: Pre-market Movers
- 11/05/20
- Fly Intel: After-Hours Movers
- 11/02/20
- Fly Intel: After-Hours Movers
- 08/10/20
- Fly Intel: After-Hours Movers
- 08/07/20
- Fly Intel: Wall Street's top stories at midday
- 12/26/20
- Week in review: How Trump's policies moved stocks
- 11/21/20
- Week in review: How Trump's policies moved stocks
- 11/05/20
- Fly Intel: Pre-market Movers
- 10/08/20
- Cytokinetics plunges following mixed results from heart drug trial
- 01/11/21
- Fly Intel: Wall Street's top stories for Monday
- 01/11/21
- Fly Intel: Wall Street's top stories at midday
- 01/11/21
- Eli Lilly and Alzheimer's research peers jump after study meets endpoint
- 12/04/20
- Delta, United, Boeing downgrades among today's top calls on Wall Street
- 12/30/20
- Fly Intel: Wall Street's top stories for Wednesday
- 12/30/20
- Fly Intel: Wall Street's top stories at midday
- 12/30/20
- AstraZeneca upgrade, Spotify target change among top calls on Wall Street
- 12/30/20
- Fly Intel: Pre-market Movers
- 12/14/20
- Fly Intel: Wall Street's top stories for Monday
- 12/14/20
- Fly Intel: Wall Street's top stories at midday
- 12/14/20
- Fly Intel: Pre-market Movers
- 12/07/20
- Fly Insider: Foot Locker, Alexion among weeks notable insider trades
- 11/18/20
- Tesla, Boeing upgrades among today's top calls on Wall Street
- 11/17/20
- Fly Intel: Wall Street's top stories for Tuesday
- 09/29/20
- Hersey, Best Buy upgrades among today's top calls on Wall Street
- 09/04/20
- Fly Intel: Wall Street's top stories for Friday
- 09/15/20
- Alexion strength attributed to takeover speculation
- 12/17/20
- Notable open interest changes for December 17th
- 11/11/20
- Notable open interest changes for November 11th
- 10/28/20
- Notable open interest changes for October 28th
- 10/27/20
- Notable open interest changes for October 27th
- 01/15/21
- Eli Lilly call volume above normal and directionally bullish
- 01/13/21
- Early notable gainers among liquid option names on January 13th
- 01/11/21
- Early notable gainers among liquid option names on January 11th
- 12/09/20
- Early notable gainers among liquid option names on December 9th
- 01/20/21
- Unusually active option classes on open January 20th
- 01/11/21
- Unusually active option classes on open January 11th
- 01/05/21
- Bristol Myers Squibb call volume above normal and directionally bullish
- 01/04/21
- Bristol Myers Squibb call buyer realizes 25% same-day gains
- 01/08/21
- Biogen put volume heavy and directionally bearish
- 11/11/20
- Early notable gainers among liquid option names on November 11th
- 11/05/20
- Unusually active option classes on open November 5th
- 09/28/20
- Early notable gainers among liquid option names on September 28th
- 12/30/20
- Unusually active option classes on open December 30th
- 12/29/20
- Unusually active option classes on open December 29th
- 12/28/20
- Unusually active option classes on open December 28th
- 12/14/20
- AstraZeneca call volume above normal and directionally bullish
- 12/14/20
- Early notable gainers among liquid option names on December 14th
- 10/20/20
- Alexion call volume above normal and directionally bullish
- 10/19/20
- Alexion call volume above normal and directionally bullish
- 09/11/20
- Alexion call volume above normal and directionally bullish
- 11/10/20
- AbbVie call volume above normal and directionally bullish
- 11/04/20
- Unusually active option classes on open November 4th
- 10/30/20
- Unusually active option classes on open October 30th
- 10/16/20
- AbbVie call volume above normal and directionally bullish
|